摘要
肾性贫血是慢性肾脏病透析患者最常见的并发症之一。目前中国透析患者贫血治疗达标率较低。纠正贫血状态,对于改善透析患者的生存质量,延长患者的生存期,具有重要意义。文章对肾性贫血中铁剂和促红细胞生成素的应用及治疗目标进行了总结,并介绍了低氧诱导因子-脯氨酰羟化酶抑制剂罗沙司他及铁调素拮抗剂等新型治疗肾性贫血药物。建议临床医生对肾性贫血患者进行个体化治疗。
Renal anemia is one of the most common complications in patients who undergo dialysis.The hemoglobin level of most of those patients do not reach the lower end of the target range.Therefore,to correct anemia is of great significance for improving the outcomes and prolonging the survival time.We summarized the applications of iron agents and erythropoiesisstimulating agents as well as the therapeutic targets.We also introduced some of the new agents such as hypoxia inducible factor prolyl hydroxylase inhibitor and hepcidin antagonist.It is recommended for clinicians to provide individualized treatment for patients with renal anemia.
作者
孙立
姚丽
SUN Li;YAO Li(Department of Nephrology,the First Affiliated Hospital of China Medical University,Shenyang 110001,China)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2020年第11期890-894,共5页
Chinese Journal of Practical Internal Medicine
基金
国家自然基金(81870505,82070763)。
